A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine

Pfizer

Status and phase: Completed; Phase 3

Conditions: Pain

Treatments: Drug: Ibuprofen/Caffeine; Drug: Ibuprofen; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT02863575

B3741002

MIG II (Other Identifier)

MIG (Other Identifier)

Details and patient eligibility

About

An efficacy study assessing analgesic effect of ibuprofen/caffeine in post-surgical dental pain.

Full description

The purpose of this study is to assess the analgesic efficacy of a fixed dose combination of ibuprofen/caffeine compared to ibuprofen alone and also to placebo.

Enrollment: 374 patients

Sex: All

Ages: 16 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males and females 16 years to 40 years of age (inclusive).
• Subjects who have undergone outpatient surgical extraction of 3 or more third molars, of which at least 2 must be a partial or complete bony mandibular impaction within 30 days of Screening and have met baseline pain criteria as described in this protocol
• Examined by the attending dentist or physician and medically cleared to participate in the study.

Exclusion criteria

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, metabolic or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing) determined by the Investigator to place the subject at increased risk including the presence or history within 2 years of screening of the following medical conditions/disorders:

  • Bleeding disorder;
  • Gastrointestinal ulcer or gastrointestinal bleeding;
  • Paralytic ileus or other gastrointestinal obstructive disorders.

• Pregnant female subjects; breastfeeding female subjects; fertile male subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception

• Hypersensitivity to ibuprofen, naproxen, aspirin, or any other NSAID, caffeine, or other component of the product.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

374 participants in 3 patient groups, including a placebo group

Ibuprofen/Caffeine

Experimental group

Description:

Ibuprofen 400 mg/ Caffeine 100 mg fixed-dose combination

Treatment:

Drug: Ibuprofen/Caffeine

Ibuprofen

Active Comparator group

Description:

Ibuprofen 400 mg

Treatment:

Drug: Ibuprofen

Placebo

Placebo Comparator group

Description:

Placebo comparator

Treatment:

Drug: Placebo